<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8900963</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1466</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Neurobiol.</journal-id>
<journal-title-group>
<journal-title>Molecular neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-7648</issn>
<issn pub-type="epub">1559-1182</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30225775</article-id>
<article-id pub-id-type="pmc">6421119</article-id>
<article-id pub-id-type="doi">10.1007/s12035-018-1344-x</article-id>
<article-id pub-id-type="manuscript">NIHMS1507039</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fragile X and APP: A Decade in Review, A Vision for the Future.</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Westmark</surname>
<given-names>Cara J.</given-names>
</name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="CR1"><label>*</label>Corresponding Author Information: Cara J. Westmark, Assistant Professor, Department of Neurology, University of Wisconsin-Madison, Medical Sciences Center, Room 3619, 1300 University Avenue, Madison, WI USA, <email>westmark@wisc.edu</email>, Phone: (608) 262-9730</corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P48">Conflict of Interest Disclosures.</p>
<p id="P49">CJW has received research funding from Lundbeck Research USA, Inc. and Merz Pharmaceuticals GmbH to test novel mGluR<sub>5</sub> inhibitors in <italic>Fmr1</italic><sup><italic>KO</italic></sup> mice.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>6</month>
<year>2020</year>
</pub-date>
<volume>56</volume>
<issue>6</issue>
<fpage>3904</fpage>
<lpage>3921</lpage>
<!--elocation-id from pubmed: 10.1007/s12035-018-1344-x-->
<abstract id="ABS1">
<p id="P1">Fragile X syndrome (FXS) is a devastating developmental disability that has profound effects on cognition, behavior and seizure susceptibility. There are currently no treatments that target the underlying cause of the disorder and recent clinical trials have been unsuccessful. In 2007, seminal work demonstrated that amyloid-beta protein precursor (APP) is dysregulated in <italic>Fmr1</italic><sup><italic>K</italic>O</sup> mice through a metabotropic glutamate receptor 5 (mGluR<sub>5</sub>)-dependent pathway. These findings raise the hypotheses that: (1) APP and/or APP metabolites are potential therapeutic targets as well as biomarkers for FXS, and (2) mGluR<sub>5</sub> inhibitors may be beneficial in the treatment of Alzheimerâ€™s disease. Herein, advances in the field over the past decade that have reproduced and greatly expanded upon these original findings are reviewed, and required experimentation to validate APP metabolites as potential disease biomarkers as well as therapeutic targets for FXS are discussed.</p>
</abstract>
<kwd-group>
<kwd>Amyloid-beta protein precursor (APP)</kwd>
<kwd>cellular prion protein (PrP<sup>C</sup>)</kwd>
<kwd>fragile X mental retardation protein (FMRP)</kwd>
<kwd>fragile X syndrome (FXS)</kwd>
<kwd>metabotropic glutamate receptor 5 (mGluR<sub>5</sub>)</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>